More OFF:
Exactly, Lucius, regarding mutual funds. I used to be totally into mutual funds before I decided to zero in on selected stocks. Vanguard Special Health Care was my major holding along with another great one Legg Mason Value Trust.
But VGHCX is in 99 stocks (of which WLA and PFE are number #1 and 2). LMVTX is big into Dell, but has 80 stocks overall.
So I finally decided, why go for the vanilla that tries to eke out a small gain in relation to the S&P 500, when I could zero in on the salsa of the mutual funds' portfolios and potentially do even better than the funds over the long term.
Funds have to play it real safe, I don't.
I sold the funds, and bought a dozen large caps and focused in as I've researched (I've only been investing for three years, and started out with BB stocks, went to small caps, and now the big boys this year).
Re: Cox2 Inhibitor. Great prospects, reported to be a blockbuster.
However, the first product to market is likely to be Celebra developed by Monsanto's Searle division. Merck is supposed to be second to market, but months, maybe a year behind.
Oh, did I mention who the partner is with Monsanto on this first Cox2 inhibitor, Celebra?
Yup, Pfizer.
Pfizer is also the partner with Warner-Lambert in one of their newest and most successful products (cholesterol lowering Lipitor).
In fact, PFE is recognized as having the best marketing force out there. |
